MRTX-1719 (MRTX1719) is novel, potential First-in-class and selective inhibitor of PRMT5/MTA complex (IC50 < 10 nM) with anticancer activity. MRTX1719 selectively inhibits the PRMT5/MTA complex with a very slow off rate and tight binding leads to prolonged PD effects in preclinical models. Greater inhibition of PRMT5 in MTAP-deleted (tumor) cells suggest the potential for an increased therapeutic index with fewer adverse events (e.g., bone marrow suppression) compared to non-PRMT5/MTA selective inhibitors

纯度：≥98%

CAS：2630904-45-7